Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
A method of treating an episode of acute exacerbation of schizophrenia by intramuscular administration of a long-acting injectable depot composition containing risperidone is provided. The method provides a substantial reduction in PANSS (both positive and negative scales) and CGI-S scores within about eight days after administration of the composition and for up to at least four weeks. The method is used to treat a subject suffering a first-time episode of or a relapse of severe to moderate symptoms associated with schizophrenia. The method does not require loading doses of risperidone in the depot composition and does not require supplementation with oral risperidone after administration of the depot composition.
1. A method of treating an episode of acute exacerbation of schizophrenia in a human subject, the method comprising administering to a subject undergoing said episode a long-acting injectable (LAI) depot composition comprising a maintenance dose of risperidone, wherein said composition is administered intramuscularly once about every 28 days or about once monthly, further wherein said episode is a relapse episode of acute exacerbation of schizophrenia, and said method comprises administering to a subject undergoing said episode a LAI depot composition comprising a maintenance dose of 25-150 mg of risperidone, DMSO, and PLGA copolymer, wherein a) >0 wt % and ≤20% of said risperidone is dissolved in said composition prior to administration; b) the PLGA copolymer has a monomer ratio of lactic acid to glycolic acid in the range from about 50:50 to about 75:25; c) before administration, the LAI depot composition has a viscosity in the range of about 0.5-7 Pa·s; d) the LAI depot composition has a mass ratio of DMSO to risperidone of about 5:1 to about 4:1; and e) the LAI depot composition has a mass ratio of risperidone to (PLGA+risperidone), expressed as the percentage of the risperidone weight with respect to total weight of the risperidone plus PLGA, in the range of about 25-35% wt.
2. The method of claim 1 , wherein said composition is administered within two weeks or less, within ten days or less, within one week or less, within five days or less, within three days or less, within two days or less, or within one day or less of occurrence of said episode of acute exacerbation of schizophrenia.
3. The method of claim 1 , wherein method a) results in reduced on-symptom days, reduced in-hospital days, and improved total PANSS as compared to methods of treatment employing risperidone-containing LAI depot composition, which is an intramuscular risperidone-containing PLGA microparticle formulation, and risperidone-containing LAI depot composition defined, which is a microparticulate risperidone-containing depot formulation intended for subcutaneous administration in adipose tissue, on a dose equivalent basis; and/or b) provides reduced total treatment-emergent adverse events (TEAEs) compared with risperidone-containing LAI depot composition, which is an intramuscular risperidone-containing PLGA microparticle formulation, and risperidone-containing LAI depot composition, which is a microparticulate risperidone-containing depot formulation intended for subcutaneous administration in adipose tissue, on a dose equivalent basis and, in a population of treated subjects, provides a lower rate of discontinuation due to TEAEs compared with placebo.
4. The method of claim 1 , wherein said administering comprises intramuscularly administering to said subject, and wherein after said administration an implant formed from said composition provides therapeutic plasma concentrations of total active moiety (risperidone and 9-OH-risperidone) within 2-24 hours after administration and continuously for a period of at least about 28 days, thereby providing significant reduction in symptoms associated with said psychosis, as determined by total PANSS, including the positive and negative scales, and CGI-S, starting from about 8 days after said administering, wherein said method excludes oral supplementation with risperidone and excludes administration of one or more loading doses of risperidone in LAI depot composition.
5. The method of claim 1 , wherein the method provides a) significantly improved PANSS total score (mean difference, 95% CI) from baseline to day 85 of −13.0 (95% CI, −17.3 to −8.8) (p<0.0001) on a placebo-adjusted basis following administration of a maintenance dose of 75 mg of risperidone in said LAI depot composition; b) significantly improved PANSS total score (mean difference, 95% CI) from baseline to day 85 of −13.3 (−17.6 to −8.9) (p<0.0001) on a placebo-adjusted basis following administration of a maintenance dose of about 100 mg of risperidone in said LAI depot composition; c) significantly improved CGI-S total score (mean difference, 95% CI) from baseline to day 85 of −0.7 (−1.0 to −0.5) (p<0.0001) on a placebo-adjusted basis following administration of a maintenance dose of about 75 mg of risperidone in said LAI depot composition; and/or d) significantly improved CGI-S total score (mean difference, 95% CI) from baseline to day 85 of −0.7 (−1.0 to −0.5) (p<0.0001) on a placebo-adjusted basis following administration of a maintenance dose of 100 mg of risperidone in said LAI depot composition.
6. The method of claim 1 , wherein said administering comprises intramuscularly administering to the subject, and wherein a) after said administration, an implant formed from said composition provides therapeutic plasma concentrations of total active moiety (risperidone and 9-OH-risperidone) within 2-24 hours after administration and continuously for a period of at least about 28 days; and b) after said administration, an implant formed from said composition provides a reduction of total PANSS score, in both the positive and negative scales, of −13.3 (−17.6 to −8.9) (p<0.0001) and a reduction of CGI-S total score of −0.7 (−1.0 to −0.5) (p<0.0001), said scores being on a placebo-adjusted basis.
7. A method of switching a subject from an oral dosing protocol to a long-acting injectable (LAI) depot composition dosing protocol, the method comprising a) identifying a subject having a psychotic disorder and receiving less than 4 mg daily of oral risperidone; b) discontinuing said oral risperidone; and c) about every four weeks or about once-monthly intramuscularly administering to said subject an amount of LAI depot composition comprising a maintenance dose of about 75 mg of risperidone, DMSO, and PLGA copolymer, wherein a) >0 wt % and ≤20% of said risperidone is dissolved in said composition prior to administration; b) the PLGA copolymer has a monomer ratio of lactic acid to glycolic acid in the range from about 50:50 to about 75:25; c) the LAI depot composition has a viscosity in the range of about 0.5-7 Pa·s; d) the LAI depot composition has a mass ratio of DMSO to risperidone of about 5:1 to about 4:1; and e) the LAI depot composition has a mass ratio of risperidone to (PLGA+risperidone), expressed as the percentage of the risperidone weight with respect to total weight of the risperidone plus PLGA, in the range of about 25-35% wt.
8. A method of switching a subject from an oral dosing protocol to a long-acting injectable (LAI) depot composition dosing protocol, the method comprising a) identifying a subject having a psychotic disorder and receiving 4 mg daily or more and/or up to about 6 mg daily of oral risperidone; b) discontinuing said oral risperidone; and c) about every four weeks or about once-monthly intramuscularly administering to said subject an amount of LAI depot composition comprising a maintenance dose of about 100 mg of risperidone, DMSO, and PLGA copolymer, wherein a) >0 wt % and ≤20% of said risperidone is dissolved in said composition prior to administration; b) the PLGA copolymer has a monomer ratio of lactic acid to glycolic acid in the range from about 50:50 to about 75:25; c) the LAI depot composition has a viscosity in the range of about 0.5-7 Pa·s; d) the LAI depot composition has a mass ratio of DMSO to risperidone of about 5:1 to about 4:1; and e) the LAI depot composition has a mass ratio of risperidone to (PLGA+risperidone), expressed as the percentage of the risperidone weight with respect to total weight of the risperidone plus PLGA, in the range of about 25-35% wt.
9. The method of claim 8 , wherein the first dose of LAI depot composition is administered within 48 h after said discontinuing.
10. The method of claim 1 , wherein the method a) excludes the step of administering one or more loading doses of risperidone in a LAI depot composition before said intramuscular administration of the LAI depot composition; and/or b) excludes the step of orally administering one or more doses of risperidone within said 28-day or monthly period.
11. The method of claim 1 wherein the subject a) is unstable and experiencing severe to moderate psychotic symptoms; b) is experiencing a first acute exacerbation of schizophrenia; c) is undergoing treatment with one or more oral antipsychotic drugs; d) has experienced prior episode(s) of acute exacerbation of schizophrenia; e) is experiencing worsening psychotic symptoms or impending relapse of psychosis; f) is experiencing a relapse of severe to moderate psychotic symptoms; and/or g) is undergoing treatment with a LAI depot composition that is different than said LAI depot composition.
12. The method of claim 1 wherein a) the composition comprises a maintenance dose of about 25 mg to about 125 mg, about 25 mg to about 100 mg, about 50 mg to about 150 mg, about 50 mg to about 125 mg, about 50 mg to about 100 mg, about 75 mg to about 150 mg, about 75 mg to about 125 mg, about 75 mg to about 100 mg, about 25 mg, about 50 mg, about 75 mg, about 100 mg, about 125 mg, or about 150 mg of risperidone; b) the LAI depot composition forms a biodegradable implant in muscle after administration; c) ≤2.5%, ≤5%, ≤7.5%, ≤10%, ≤20% of the risperidone is dissolved in said composition before administration; d) >0%, ≥0.5%, ≥1%, ≥5%, ≥10%, ≥15%, or up to about 20% wt of the risperidone is dissolved in said composition before administration; e) the PLGA copolymer has a monomer ratio of lactic acid to glycolic acid in the range from about 35:65 to about 75:25, about 45:55 to about 70:30, about 50:50 to about 65:35, or about 65:35 to about 75:25, 45:55 to 55:45, or 48:52 to 52:48, or about 50:50, 50:50±10%, or 75:25±10%; f) before administration, a polymeric solution of DMSO and PLGA used to form the LAI depot composition has a viscosity in the range of about 0.5-7 Pa·s, about 0.5-4 Pa·s, about 0.7-4 Pa·s, about 0.5-3.0 Pa·s, about 0.7-3.0 Pa·s, about 1.5-2.1 Pa·s±10%, about 1.5 to about 2.5 Pa·s, about 1.5 to about 2.3 Pa·s, or about 1.7-1.8 Pa·s ±10%; g) the PLGA copolymer has an inherent viscosity in the range of 0.20-0.60 dl/g, about 0.30-0.55 dl/g, about 0.36-0.52 dl/g, about 0.40-0.58 dl/g, or about 0.46-0.51 dl/g measured in chloroform at 30° C. and at a concentration of 0.5% wt with a Ubbelohde size 0B glass capillary viscometer; h) the LAI depot composition has a mass ratio of DMSO to risperidone of about 4.6:1 to about 4.8:1, about 4.6:1 to about 4.7:1, about 4.67:1, about 4.66:1 or about 4.68:1, or about 4.66:1; i) the LAI depot composition has a mass ratio of risperidone to (PLGA+risperidone), expressed as the percentage of the risperidone weight with respect to total weight of the risperidone plus PLGA, in the range of about 30-35%, about 31-35%, about 32-34% or about 33% wt; j) the PLGA copolymer is end-capped with an ester group or a carboxyl group; k) the content of risperidone in the formulation is about 10-15% wt, about 11-14% wt, about 12-14% wt, or about 13% wt; l) the PLGA polymer has been irradiated with beta or gamma radiation in the range of 10-30 KGy, 15-30 Kgy, or between 16-25 Kgy±10%; m) the composition is sterile; n) the injectable composition continuously provides therapeutically effective plasma levels of total active moiety in the subject throughout a dosing period of at least four weeks beginning from the day of administration; o) before administration, the LAI depot composition has a viscosity in the range of about 1.0-7.0 Pa·s, about 1.5-7.0 Pa·s, or about 1.8-6.5 Pa·s; p) the mass ratio of solvent (DMSO) to polymeric solution, expressed as the weight percentage of solvent with respect to the weight of polymer+solvent, is about 50-75%, about 65-75%, about 60-70%, about 68-72%, or about 70%; q) the concentration of PLGA in the LAI depot composition is in the range of 24%-40% wt, 24%-30% wt, 25-27% wt or 26% wt, (expressed as the percentage of polymer weight based on total composition weight); and/or r) the content of DMSO in the injectable depot composition is about 55-65% wt, about 57-63% wt, about 60-62% wt, or about 61% wt based upon the total weight of the composition.
13. A method of treating an episode of acute exacerbation of schizophrenia in a human subject, the method comprising administering to a subject undergoing said episode a long-acting injectable (LAI) depot composition comprising a maintenance dose of risperidone, wherein said composition is administered intramuscularly once about every 28 days or about once monthly, the method further comprising a) providing a container comprising DMSO and a container comprising risperidone and said PLGA copolymer, and mixing the contents of said containers to form said injectable depot composition, then administering said injectable depot composition; or b) providing a container comprising DMSO, a container comprising risperidone, and a container comprising said PLGA copolymer, and mixing the contents of the containers to form said injectable depot composition, then administering said injectable depot composition.
14. The method of claim 13 , wherein said containers are included in a kit.
15. The method of claim 14 , wherein said kit comprises a single dose of risperidone.
16. The method of claim 7 , wherein the first dose of LAI depot composition is administered within 24 to 48 h or within 24 h after said discontinuing.
17. The method of claim 4 , wherein the method provides a) significantly improved PANSS total score (mean difference, 95% CI) from baseline to day 85 of −13.0 (95% CI, −17.3 to −8.8) (p<0.0001) on a placebo-adjusted basis following administration of a maintenance dose of 75 mg of risperidone in said LAI depot composition; b) significantly improved PANSS total score (mean difference, 95% CI) from baseline to day 85 of −13.3 (−17.6 to −8.9) (p<0.0001) on a placebo-adjusted basis following administration of a maintenance dose of about 100 mg of risperidone in said LAI depot composition; c) significantly improved CGI-S total score (mean difference, 95% CI) from baseline to day 85 of −0.7 (−1.0 to −0.5) (p<0.0001) on a placebo-adjusted basis following administration of a maintenance dose of about 75 mg of risperidone in said LAI depot composition; and/or d) significantly improved CGI-S total score (mean difference, 95% CI) from baseline to day 85 of −0.7 (−1.0 to −0.5) (p<0.0001) on a placebo-adjusted basis following administration of a maintenance dose of 100 mg of risperidone in said LAI depot composition.